L 29/40 EN Official Journal of the European Union 4.2.2016 Article 94 Protection of data submitted to obtain an authorisation to put a pharmaceutical product (1) on the market 1. Each Party shall implement a comprehensive system to guarantee the confidentiality, non-disclosure and nonreliance of data submitted for the purpose of obtaining an authorisation to put a pharmaceutical product on the market. 2. Each Party shall ensure that any information submitted to obtain an authorisation to put a pharmaceutical product, as referred to in Article 39(3) of the TRIPS Agreement, on the market remains undisclosed to third parties and benefits from a period of at least six years of protection against unfair commercial use starting from the date of the grant of a marketing authorisation in either Party. To that end, (a) during a period of at least six years starting from the date of the grant of a marketing authorisation, no person or entity, whether public or private, other than the person or entity who submitted such undisclosed data, shall be allowed to rely directly or indirectly on such data, without the explicit consent of the person or entity who submitted this data, in support of an application for the authorisation to put a pharmaceutical product on the market; (b) during a period of at least six years starting from the date of the grant of a marketing authorisation, any subsequent application for the authorisation to put a pharmaceutical product on the market shall not be granted, unless the subsequent applicant submits his own data, or data used with authorisation of the holder of the first authorisation, meeting the same requirements as the first applicant. During this six-year period, products registered without submission of such data shall be removed from the market until the requirements are met. Article 95 Data protection on plant protection products and rules on avoidance of duplicative testing 1. The Parties shall determine safety and efficacy requirements before authorising the placing on the market of plant protection products. 2. Each Party shall recognise a temporary data protection right to the owner of a test or study report submitted for the first time to obtain a marketing authorisation for a plant protection product. During the period of validity of the data protection right, the test or study report shall not be used for the benefit of any other person aiming to achieve a marketing authorisation for a plant protection product, except when the explicit consent of the owner is provided. This right shall be hereinafter referred to as ‘data protection’. 3. The test or study report shall: (a) be necessary for the authorisation or for an amendment of an authorisation in order to allow the use on other crops, and (b) be certified as compliant with the principles of good laboratory practice or of good experimental practice. 4. The term of data protection for plant protection products in a Party shall be 10 years starting on the date of the first authorisation in that Party. Longer periods may be granted by each Party in order to encourage the authorisation of, for instance, low risk plant protection products or minor uses. 5. A test or study shall also be protected if it was necessary for the renewal or review of an authorisation. 6. The Parties shall lay down rules on the avoidance of duplicative testing on vertebrate animals. Any applicant intending to perform tests and studies involving vertebrate animals shall take the necessary measures to verify that those tests and studies have not already been performed or initiated. (1) The term ‘pharmaceutical product’ in this Chapter refers, in the case of the European Union, to medicinal products as defined in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.

Select target paragraph3

Connect to a paragraph
Connect to an entity
Disable highlights
Add to table of contents